

**UNIVERSITI TEKNOLOGI MARA**

**TUMORIGENIC ACTIVITY OF  
EOSINOPHILS IN BREAST  
CANCER MOUSE MODEL  
POST-IRRADIATION THERAPY**

**NURHASLINA BINTI HASAN**

Thesis submitted in fulfillment  
of the requirements for the degree of  
**Doctor of Philosophy**  
**(Medicine)**

**Faculty of Medicine**

**June 2022**

## ABSTRACT

COVID-19 pandemic forcing everyone to adapt to a new norm, including cancer management. Due to the minimal risk of cross-infection, hypofractionation radiotherapy was suggested, although its efficacy and toxicity are still unknown. The potential and mechanism of action of radiotherapy on the tumour microenvironment (TME) has become a matter of concern as it either has the capability to induce immunogenic cell death that might attract the systemic immune response known as abscopal effect, or it just an unintentional or bystander effect. One unsolved finding related to radiotherapy and the TME was an increased gene expression of Eosinophil-associated ribonuclease family 11 (EAR11) following 7.5 Gy irradiation that potentially enables eosinophils to modulate immune response. However, up to date, the role and the recruitment of eosinophils remain unclear. Thus, this present study was divided into three main objectives; 1) to develop the custom-made lead shield for targeted irradiation of breast cancer mouse model based on calorimetric changes of Gafchromic film; 2) to investigate the effect of single targeted 2 Gy and 8 Gy absorbed doses of gamma irradiation on the circulating immune cells particularly eosinophils and those infiltrating the TME's and 3) to investigate the effect of IL-33 sensitisation alone or with the combination of radiotherapy on the immune cell recruitment and the tumour progression. Objectives 2 and 3 also measured the cytokine concentration correlated to either pro- or anti-tumorigenic activity. As a result, 28 Gy and 75 Gy delivery doses were required to achieve the respective 2 Gy and 8 Gy absorbed doses, using the 5 cm thickness of the lead shield. In Study 2, the untreated mice tumour model presented with an unaffected systemic immune population and significant splenomegaly. The early response of single targeted irradiation was reduced systemic total white blood cells (TWBC) with a significant decrease in eosinophils and basophils' absolute count and percentage. Subsequently, the exposure with 8 Gy gamma irradiation in the tumour model significantly increased the percentage of systemic neutrophils and monocyte. Overall, the immune suppression was dose-dependent, with 8 Gy irradiation shown more significant suppression compared to 2 Gy irradiation with both doses presented with a short-term immunosuppression effect. In contrast, irradiation-treated groups showed a significant decrease in neutrophils but an increased lymphocyte percentage within the TME. In line with these findings was a declined in protumorigenic cytokines that are IL-6, GM-CSF, and VEGF. In Study 3, instead of inducing the eosinophils, the tumour model sensitised with IL-33 presented with systemic neutrophilia and lymphopenia. The sensitised and the non-sensitised tumour model exposed to 8 Gy gamma irradiation showed a similar immune suppressive effect except for significant temporary neutropenia. There was a significant increase in CD45<sup>+</sup> cells and neutrophils in acute phase compared to early phase across the sensitised tumour models with or without irradiation treatment. A significantly slower tumour growth was observed in synergistic effect between IL-33 sensitisation and single targeted 8 Gy irradiation. As conclusion, the single targeted 8 Gy gamma irradiation produced using the customised lead shield, caused an increased eosinophil percentage within the TME with the concentration of cytokines possess the anti-tumorigenic activity. Subsequently, IL-33 triggered the neutrophils infiltration instead of eosinophil that suppressed the lymphocyte population within the TME. However, further investigation with a more extended experimental period is needed to understand the detailed mechanism.

## ACKNOWLEDGEMENT

*Bismillahirrahmannirrahim.* All praise to Allah for granting me the courage and to make my part-time PhD journey smooth and sailing, Alhamdulillah. This journey reminds me of my late father who shared a significant verse from al-Quran since I was an undergraduate 'And when you have decided, then rely upon Allah' (3:159).

First of all, my sincere appreciation to my supervisor, Assoc. Prof. Dr Mohammad Johari Bin Ibahim. Thank you, thank you and thank you so much. Thank you for your trust and endless motivation throughout this journey. Thank you for being highly supportive. May Allah reward you with unending goodness and bless you with great success, *insyaAllah*.

To both my co-supervisor; Assoc. Prof. Dr Narimah Abd. Hamid Hassani, thank you for lending me your ear, motivating me when I am down, sharing your jokes that make me smile and Prof. Dr Effat Omar, thank you for always being available when I need your guidance, thank you for sparing your precious time. My highest admiration for both of you and I wish I could be as committed and kind. May Allah reward both of you with goodness and bless you with success, *insyaAllah*.

Special thanks to my internship sisters, Nur Najwa Aliya and Nur Suraya, both from the Faculty of Applied Science, Universiti Teknologi MARA for assisting me no matter when (until midnight or starting 3.30 in the morning and the most thrilled one during the implementation of the first movement control order). No words can describe how grateful I am to have both of you by my side. I am indebted to Mr Hizwan Nizam Abd Rahman, from Faculty of Pharmacy, Universiti Teknologi MARA & Mr Ahmad Takim Saring, from Pusat Sains Nuklear, Universiti Kebangsaan Malaysia. I also would like to thank my PhD-mate, Nur Fatimah Ronny Sham, for your endless assistance. Thanks also to LACU and IMMB staffs and students for your kind assistance. May Allah rewards all of you with goodness and blesses you with success, *insyaAllah*.

My special dedication goes to my very dear late parents, Hasan Bin Shuhada and Salbiyah Binti Haron. No words can describe how grateful am I to have parents like you. I wish and pray that I can educate my children as you did. I really miss both of you. 'My Lord! Bestow on them Your mercy, as they did bring me up when I was young. Amin.

Finally, this thesis is dedicated to my beloved family, my husband Mohd Jaffri Bin Razai, for his constant presence and unconditional support, my beautiful children, Allya Khadijah, Asiah Adawiyah, Abu Ubaidah and Aesyah Medina. Please forgive your mother for turning into several colours throughout this journey. 'O, Lord! Give us spouse and children who will be the joy (comfort) of our eyes'

Amin ya Rabbal-A'lamin.

# TABLE OF CONTENTS

	<b>Page</b>
<b>CONFIRMATION BY PANEL OF EXAMINERS</b>	<b>ii</b>
<b>AUTHOR'S DECLARATION</b>	<b>iii</b>
<b>ABSTRACT</b>	<b>iv</b>
<b>ACKNOWLEDGEMENT</b>	<b>v</b>
<b>TABLE OF CONTENTS</b>	<b>vi</b>
<b>LIST OF TABLES</b>	<b>xi</b>
<b>LIST OF FIGURES</b>	<b>xii</b>
<b>LIST OF ABBREVIATIONS</b>	<b>xviii</b>
<b>LIST OF SYMBOLS</b>	<b>1</b>
<b>CHAPTER ONE INTRODUCTION</b>	<b>1</b>
1.1 Research Background	1
1.2 Problem Statement	3
1.3 Research Question	4
1.4 Research Hypothesis	4
1.5 Study Objective	5
1.5.1 General Objective	5
1.5.2 Specific Objective	5
1.6 Significance of Study	6
1.7 Scope and Limitation of Study	6
<b>CHAPTER TWO LITERATURE REVIEW</b>	<b>7</b>
2.1 Breast Cancer	7
2.1.1 Epidemiology	7
2.1.2 Risk Factor	8
2.1.3 Cancer Biology	9
2.1.4 Breast Cancer Assessment and Diagnosis	11
2.1.5 Management of Breast Cancer	12
2.2 Radiation Therapy	13

2.2.1	Fundamental of Radiation	15
2.2.2	Gamma Radiation	17
2.3	Tumour Characteristic	20
2.3.1	Tumour Model	20
2.3.2	Tumour Microenvironment	21
2.4	Radiotherapy, Tumour Microenvironment, and Immune Cells	22
2.4.1	Radiotherapy and Tumour Microenvironment	22
2.4.2	Tumour Immune Microenvironment (TiME)	26
2.4.3	Radiobiology Model	36
 <b>CHAPTER THREE RESEARCH METHODOLOGY</b>		<b>38</b>
3.1	Place of Study	38
3.2	Ethical Approval	38
3.3	Research Materials	38
3.3.1	EMT6 Cell Lines	38
3.3.2	Animals	39
3.3.3	Gamma Irradiator	39
3.3.4	Chemicals, Reagent and Equipment	40
3.4	Study Design	46
3.5	Sample Size	46
3.6	Optimisation of Mouse Bearing Tumour Model	48
3.6.1	EMT6 Cell Culture	48
3.6.2	EMT6 Cells Inoculation	49
3.6.3	Measurement of Tumour Volume	49
3.7	Study 1 Development of Customised Lead Shield and Strainer for 2 and 8 Gy Targeted Gamma-ray Irradiation.	51
3.7.1	Fabrication of Lead Shield	51
3.7.2	Fabrication of Mouse Strainer	51
3.7.3	Determination of Delivery and Absorbed Doses using EBT Gafchromic film	52
3.8	Experimental Protocol for Study 2 and Study 3	54
3.8.1	Study 2: To Investigate the Effect of Different Doses of Targeted Gamma Irradiation on Immune Response and Cancer Progression	54
3.8.2	Study 3: To Investigate the Effects of IL-33 Sensitisation with or	